{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:41:45Z","timestamp":1773290505591,"version":"3.50.1"},"reference-count":40,"publisher":"FapUNIFESP (SciELO)","issue":"4","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz J Med Biol Res"],"DOI":"10.1590\/1414-431x20165356","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T00:02:00Z","timestamp":1490313720000},"source":"Crossref","is-referenced-by-count":30,"title":["Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer"],"prefix":"10.1590","volume":"50","author":[{"given":"M.","family":"Li","sequence":"first","affiliation":[{"name":"Second People's Hospital of Huaian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.M.","family":"Feng","sequence":"additional","affiliation":[{"name":"Second People's Hospital of Huaian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.Q.","family":"Fang","sequence":"additional","affiliation":[{"name":"Second People's Hospital of Huaian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2017]]},"reference":[{"key":"ref1","series-title":"World cancer report Chapter 1.1","year":"2014"},{"key":"ref2","article-title":"Assessing the acceptability, feasibility, and effectiveness of a tablet-based cervical cancer educational intervention","author":"Caster MM","year":"2015","journal-title":"J Cancer Educ"},{"key":"ref3","first-page":"33","article-title":"HPV vaccination and testing","volume":"3","author":"Kent A","year":"2010","journal-title":"Rev Obstet Gynecol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4103\/0971-5851.92808","article-title":"An overview of prevention and early detection of cervical cancers","volume":"32","author":"Mishra GA","year":"2011","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/09513590.2011.558953","article-title":"Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature","volume":"27","author":"Gadducci A","year":"2011","journal-title":"Gynecol Endocrinol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/jcp.21066","article-title":"Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications","volume":"212","author":"Sigalotti L","year":"2007","journal-title":"J Cell Physiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1476-4598-4-38","article-title":"Epigenetics of cervical cancer. An overview and therapeutic perspectives","volume":"4","author":"Duenas-Gonzalez A","year":"2005","journal-title":"Mol Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/1471-2407-13-520","article-title":"High expression of ezrin predicts poor prognosis in uterine cervical cancer","volume":"13","author":"Kong J","year":"2013","journal-title":"BMC Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1593\/neo.11518","article-title":"The ezrin metastatic phenotype is associated with the initiation of protein translation","volume":"14","author":"Briggs JW","year":"2012","journal-title":"Neoplasia"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3892\/mmr.2013.1490","article-title":"Association between ezrin protein expression and the prognosis of colorectal adenocarcinoma","volume":"8","author":"Lin LJ","year":"2013","journal-title":"Mol Med Rep"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fonc.2014.00138","article-title":"Extracellular galectin-3 in tumor progression and metastasis","volume":"4","author":"Fortuna-Costa A","year":"2014","journal-title":"Front Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/glycob\/cwu086","article-title":"Galectin-3 in angiogenesis and metastasis","volume":"24","author":"Funasaka T","year":"2014","journal-title":"Glycobiology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.25945","article-title":"The role of galectins in colorectal cancer progression","volume":"129","author":"Barrow H","year":"2011","journal-title":"Int J Cancer"},{"key":"ref14","first-page":"119","article-title":"Galectins in hematological malignancies","volume":"1","author":"St-Pierre Y","year":"2011","journal-title":"Am J Blood Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3109\/09513590.2014.898054","article-title":"Vascular endothelial growth factor C enhances cervical cancer cell invasiveness via upregulation of galectin-3 protein","volume":"30","author":"Liu J","year":"2014","journal-title":"Gynecol Endocrinol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.compmedimag.2013.08.001","article-title":"A fusion-based approach for uterine cervical cancer histology image classification","volume":"37","author":"De S","year":"2013","journal-title":"Comput Med Imaging Graph"},{"key":"ref17","series-title":"Robbins basic pathology","author":"Kumar V","year":"2007","edition":"8th edn"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ygyno.2015.01.548","article-title":"Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A)","volume":"137","author":"Kato T","year":"2015","journal-title":"Gynecol Oncol"},{"key":"ref19","first-page":"5830","article-title":"Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases","volume":"59","author":"Zhong H","year":"1999","journal-title":"Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1868-7083-4-13","article-title":"Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix","volume":"4","author":"Saavedra KP","year":"2012","journal-title":"Clin Epigenetics"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.7314\/APJCP.2013.14.5.2753","article-title":"Meta-analysis of associations of the ezrin gene with human osteosarcoma response to chemotherapy and prognosis","volume":"14","author":"Wang Z","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"14700","DOI":"10.1038\/srep14700","article-title":"Ezrin is a major regulator of membrane tension in epithelial cells","volume":"5","author":"Rouven Bruckner B","year":"2015","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s13277-011-0228-8","article-title":"Expression and significance of Six1 and Ezrin in cervical cancer tissue","volume":"32","author":"Tan J","year":"2011","journal-title":"Tumour Biol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/onc.2008.437","article-title":"The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC","volume":"28","author":"Ren L","year":"2009","journal-title":"Oncogene"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"19631","DOI":"10.18632\/oncotarget.7779","article-title":"Ezrin contributes to cervical cancer progression through induction of epithelial-mesenchymal transition","volume":"7","author":"Kong J","year":"2016","journal-title":"Oncotarget"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbagen.2009.07.005","article-title":"Dynamics of galectin-3 in the nucleus and cytoplasm","volume":"1800","author":"Haudek KC","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.2353\/ajpath.2010.090353","article-title":"Diagnostic utility of galectin-3 in thyroid cancer","volume":"176","author":"Chiu CG","year":"2010","journal-title":"Am J Pathol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2152\/jmi.57.152","article-title":"Clinical significance of Galectin-3 in clear cell renal cell carcinoma","volume":"57","author":"Sakaki M","year":"2010","journal-title":"J Med Invest"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12029-010-9189-1","article-title":"Immunoexpression of galectin-3 in colorectal cancer and its relationship with survival","volume":"42","author":"Zaia Povegliano L","year":"2011","journal-title":"J Gastrointest Cancer"},{"key":"ref30","first-page":"69","article-title":"Expression of galectin-3 in gastric adenocarcinoma","volume":"140","author":"Gomes TS","year":"2014","journal-title":"Indian J Med Res"},{"key":"ref31","first-page":"2289","article-title":"Galectin-3 expression in colorectal cancer: relation to invasion and metastasis","volume":"27","author":"Tsuboi K","year":"2007","journal-title":"Anticancer Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e27346","DOI":"10.1371\/journal.pone.0027346","article-title":"The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT\/beta-catenin signaling and is frequently silenced in multiple tumors","volume":"6","author":"Shu XS","year":"2011","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1471-4906(02)02232-9","article-title":"Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?","volume":"23","author":"Rabinovich GA","year":"2002","journal-title":"Trends Immunol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e103482","DOI":"10.1371\/journal.pone.0103482","article-title":"Galectin-3 as a marker and potential therapeutic target in breast cancer","volume":"9","author":"Zhang H","year":"2014","journal-title":"PLoS One"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4049\/jimmunol.176.2.778","article-title":"Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death","volume":"176","author":"Stillman BN","year":"2006","journal-title":"J Immunol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e0129119","DOI":"10.1371\/journal.pone.0129119","article-title":"Galectin-1, -3 and -9 expression and clinical significance in squamous cervical cancer","volume":"10","author":"Punt S","year":"2015","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00432-005-0069-1","article-title":"Decreased galectin-3 expression during the progression of cervical neoplasia","volume":"132","author":"Lee JW","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1016\/j.humpath.2013.05.020","article-title":"Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior","volume":"44","author":"Righi A","year":"2013","journal-title":"Hum Pathol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.humpath.2012.04.010","article-title":"Galectin 1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer","volume":"44","author":"Kim HJ","year":"2013","journal-title":"Hum Pathol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e1100","DOI":"10.1038\/cddis.2014.68","article-title":"Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors","volume":"5","author":"Veschi V","year":"2014","journal-title":"Cell Death Dis"}],"container-title":["Brazilian Journal of Medical and Biological Research"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/bjmbr\/v50n4\/1414-431X-bjmbr-1414-431X20165356.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T08:52:11Z","timestamp":1601801531000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0100-879X2017000400601&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017]]}},"alternative-id":["S0100-879X2017000400601"],"URL":"https:\/\/doi.org\/10.1590\/1414-431x20165356","relation":{},"ISSN":["1414-431X","0100-879X"],"issn-type":[{"value":"1414-431X","type":"electronic"},{"value":"0100-879X","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]},"article-number":"e5356"}}